Answers are grounded in this paper and cite their sources.
ACUTE nonlymphocytic leukemia is an increasingly common complication of therapy with alkylating agents or ionizing radiation. Incidences as high as 5 per cent have been reported in patents with Hodgkin's disease who were treated with combined-modality therapy.1 Secondary leukemias are becoming increasingly common in patients treated with alkylating agents for multiple myeloma,2 ovarian carcinoma, and carcinoma of the breast. Unlike patients with "primary" acute nonlymphocytic leukemia, those with the secondary form of the disease rarely respond to conventional regimens for inducing remission. Reported rates of remission induction are in the neighborhood of 10 per cent, with median survival periods of . . .
No takes yet. Share an insight, caveat, or question.
Preisler et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: